A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Trial Details

NCT ID
NCT06875310
Phase
PHASE3
Sponsor
Mirati Therapeutics Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Adagrasib
  • Pembrolizumab
  • Carboplatin
  • Pemetrexed
  • Placebo
  • Cisplatin
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Springdale, Arkansas, United States|36.18674,-94.12881
  • Fullerton, California, United States|33.87029,-117.92534
  • Denver, Colorado, United States|39.73915,-104.9847
  • Newark, Delaware, United States|39.68372,-75.74966

Key Eligibility Criteria

  • Histologically or cytologically confirmed diagnosis of non-squamous NSCLC with evidence of KRAS G12C mutation via tumor sample and/or circulating t…
  • Locally advanced or metastatic disease.
  • Measurable disease via computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria of at least 1 lesion.
  • No prior systemic anti-cancer therapy given for advanced or metastatic disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →